Last reviewed · How we verify
TUCATINIB
At a glance
| Generic name | TUCATINIB |
|---|---|
| Drug class | Kinase Inhibitor [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 2020 |
Approved indications
Common side effects
- Diarrhea
- Palmar-plantar erythrodysesthesia syndrome
- Nausea
- Hepatotoxicity
- Vomiting
- Stomatitis
- Decreased appetite
- Anemia
- Rash
- Arthralgia
- Creatinine increased
- Weight decreased
Serious adverse events
- Diarrhea
- Vomiting
- Nausea
- Abdominal pain
- Seizure
- Sudden death
- Sepsis
- Dehydration
- Cardiogenic shock
Key clinical trials
- Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) (PHASE2)
- Phase Ib/II Study of Zanidatamab Plus Tucatinib and Chemotherapy in HER2-Positive Advanced Breast Cancer (PHASE1, PHASE2)
- A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer (PHASE2)
- Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer (PHASE2)
- TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (PHASE2)
- Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib (PHASE2)
- A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors (PHASE2)
- A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TUCATINIB CI brief — competitive landscape report
- TUCATINIB updates RSS · CI watch RSS